ENGENE HOLDINGS INC NasdaqCM:ENGN enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare